Viking Therapeutics: A Closer Look at Its Prospects and Performance

Core Insights - Viking Therapeutics is a biotech company focused on innovative treatments for metabolic and endocrine disorders, particularly advancing its VK2735 program, a dual GLP-1/GIP agonist for obesity and diabetes [1] Stock Performance - Jefferies reiterated a "Buy" rating for VKTX on March 12, 2026, with the stock priced at $35.49, following a 16.5% rise in February after the release of the fourth-quarter earnings [2] - The current stock price of VKTX is $35.36, reflecting a decrease of approximately 1.13%, with a market capitalization of around $4.09 billion [4] - Over the past year, VKTX has fluctuated between a high of $43.15 and a low of $18.92, indicating significant volatility in its stock performance [4] Drug Development Focus - The VK2735 program, especially its oral formulation, is a key focus for investors, despite previous market disappointments with top-line results [3] - Viking Therapeutics is conducting two Phase 3 trials for the subcutaneous formulation of VK2735, with a maintenance study planned for 2026 to assess the tolerability of the oral formulation [3]